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Substitutions were engineered individually and in combinations at the fusion loop, receptor-binding domain and a stem-helix structure of the
envelope protein of a West Nile virus strain, NY99, and their effects on mouse virulence and presentation of epitopes recognized by monoclonal
antibodies (MAbs) were assessed. A single substitution within the fusion loop (L107F) attenuated mouse neuroinvasiveness of NY99. No
substitutions attenuated NY99 neurovirulence. The L107F mutation also abolished binding of a non-neutralizing MAb, 3D9, whose epitope had
not been previously identified. MAb 3D9 was subsequently shown to be broadly cross-reactive with other flaviviruses, consistent with binding
near the highly conserved fusion loop.
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MutagenesisIntroduction
The genus Flavivirus, family Flaviviridae, comprises ap-
proximately 70 virus species that are classified into mosquito-
borne, tick-borne and “no known vector” groups. Many
flaviviruses, including West Nile virus (WNV), are significant
agents of human and animal disease. During the last decade,
considerable effort has been focused on the application of
molecular biological and structural techniques to identify
specific determinants of flavivirus attenuation that may
facilitate the rational design of novel vaccine candidates or
antiviral therapies (Chang et al., 2004). The best characterized⁎ Corresponding author. Department of Microbiology and Immunology,
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77555-0609, USA. Fax: +1 409 747 2437.
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doi:10.1016/j.virol.2006.05.025of the flavivirus proteins is the envelope (E) protein which plays
important roles in flavivirus attachment to and membrane fusion
with target cells. Mutations in E have been associated with
attenuation of many flaviviruses.
All flavivirus E proteins share similar structure and func-
tions, making it likely that mutations that attenuate one virus
may have similar effects for others (Rey et al., 1995;Modis et al.,
2003). This rationale has been used in the development of a
leading WNV vaccine candidate, Chimerivax®-WN (Arroyo et
al., 2004). This is a chimeric, live attenuated vaccine in which
the prM and E protein genes of NY99 WNV have been subs-
tituted into an infectious clone based on the attenuated yellow
fever virus (YFV) 17D vaccine strain, which is attenuated for
neuroinvasiveness but retains neurovirulence in a mouse model.
To further improve the safety of this vaccine candidate,
additional E protein substitutions associated with attenuation
of other flaviviruses were incorporated into the NY99 E protein
Table 1
Neuroinvasion and neurovirulence characteristics in 3- to 4-week-old female
NIH Swiss mice of West Nile virus NY99 infectious clone-derived virus and
engineered variants encoding E protein substitutions
Virus i.p. LD50
(pfu)




i.c. AST ± SDa
(days)
NY99ic 1.3 9.5 ± 0.8 1.3 7.0 ± 1.3
L107F >1000 b 9.0 ± 0.0 3.1 7.4 ± 1.8
A316V 1.3 9.5 ± 1.0 nd nd
K440R 0.3 7.9 ± 1.1 nd nd
A316V/
K440R














>1000b (no deaths) nd nd
a Average survival time ± standard deviation for all animals that died.
b Virus inoculation caused scattered mortality in several different dose groups
and did not yield a true LD50 value.
c mb-A and -B viruses were recovered from individual mice that died
following i.p. inoculation with the L107F/A316V/K440R variant. mb-A
encoded a mixed L/F sequence at residue 107, while mb-B retained the
substituted F. nd—not determined.
36 S. Zhang et al. / Virology 353 (2006) 35–40in three regions—the fusion loop (L107F), the receptor-binding
domain III (A316V) and a stem helix (K440R). The L107F
substitution completely attenuated mouse neurovirulence, and a
combination of A316V/K440R substitutions also caused some
attenuation, compared to the 17D vaccine control (Arroyo et al.,
2004). The study described here aimed to determine the effects
of these E protein substitutions on the virulence of WNVand on
the presentation of E protein epitopes using an infectious clone
based on a New York 1999 WNV isolate.
Results
Construction and recovery of WNV NY99 E protein mutants
The NY99 infectious clone (NY99ic) used here and
protocols for recovery of infectious virus have been described
elsewhere, as have methods for site-directed mutagenesis for
generation of infectious clone plasmids encoding single or
multiple substitutions (Beasley et al., 2005). Plasmids were
constructed encoding E protein substitutions L107F, A316V or
K440R individually or in the combinations A316V/K440R and
L107F/A316V/K440R. Each mutant and wild-type NY99ic was
recovered 4 or 5 days after electroporation of transcribed RNA
into Vero cells and observation of significant cytopathic effect
(>50%) in cell monolayers. Titers were determined by plaque
assay in Vero cells and were similar for mutant viruses and the
wild-type control (approximately 105 to 106 pfu/mL). The prM
and E protein genes of recovered viruses were RT-PCR ampli-
fied and sequenced to confirm the presence of the introduced
substitutions. No additional mutations compared to the NY99ic
sequence were identified in any of the mutant variants or the
wild-type control, and the introduced amino acid substitutions
were stable through five additional Vero cell passages. Com-
plete genome sequences were also determined for the recovered
L107F and L107F/A316V/K440R variants, and no additional
mutations were identified, confirming the stability of the WNV
infectious clone genome sequence.
Mouse virulence properties of mutant and NY99ic viruses
Consistent with previous studies (Beasley et al., 2005),
NY99ic was highly neuroinvasive and neurovirulent when
inoculated intraperitoneally (i.p.) or intracranially (i.c.) in female
NIH Swiss mice. Only the L107F mutant and the triple mutant
were attenuated for neuroinvasiveness (Table 1), causing some
mortality across the range of virus doses. This pattern of ragged
mortality has been observed for some attenuated wild-type line-
age 1 WNV strains (Beasley et al., 2002). These mutants were
also inoculated i.c., and none was attenuated for neurovirulence
compared to NY99ic (Table 1).
Reversions at residue 107 during in vivo replication
To assess the stability of the attenuating L107F substitution
and identify possible reversion to wild-type sequence at this
site, brains were harvested from three mice, designated A, B and
C, that died following infection with the triple L107F/A316V/K440R mutant virus. RT-PCR products corresponding to the
prM and E protein genes were directly amplified from
homogenized brain tissue and sequenced. For mouse B, there
was no evidence of reversion at any of the mutated residues.
However, sequence chromatograms of virus recovered from
mouse A and, to a lesser extent, mouse C indicated a mixed
sequence at the 107 residue (Fig. 1). PCR products from each of
the homogenates were cloned into the pGEM-T(Easy) vector,
and five clones were sequenced for each. For mice A and C,
three clones and one clone, respectively, encoded the wild-type
L107 sequence.
Variants A and B were subsequently inoculated into mice to
determine their i.p. LD50 values. Variant B (F at residue 107)
retained the highly attenuated phenotype of the triple mutant
parental virus, while variant A (mixed L/F at residue 107) had a
lowered LD50 of 79 pfu, consistent with the presence of
revertant virus in the population. Overall, these observations
suggested that (1) WNVencoding the L107F substitution is able
to invade the central nervous system, albeit at low frequency,
and (2) that the L107F substitution is not completely stable in
the animal host, suggesting that reversions to the virulent wild-
type sequence may occur.
Replication and virulence of NY99ic virus and neuroinvasion
attenuated variants following i.c. inoculation
Although i.c. LD50 values for the attenuated L107F and
L107F/A316V/K440R variants did not differ significantly from
NY99ic, the kinetics of replication and stability of the L107F
Fig. 1. Sequence chromatograms showing the region encoding residue 107 of
the WNV E protein for RT-PCR products obtained from brains of three mice
(A–C) that died following peripheral inoculation with the L107F/A316V/
K440R triple mutant virus. The wild-type sequence for this codon is C–T–A.
The mutant sequence (T–T–C) is clear in product from mouse B, while mouse
A encodes a mixed sequence (C/T–T–C/A). Smaller peaks indicating a mixed
sequence are also evident for mouse C.
37S. Zhang et al. / Virology 353 (2006) 35–40substitution following i.c. inoculation were compared. Groups
of ten mice were inoculated i.c. with 1000 pfu of virus, and virus
titers in brains of three mice at each of days 2 and 5 post-
infection were compared. Remaining mice in each group were
left to assess lethal outcome.
At day 2 post-infection, virus titers in brains of mice infected
with L107F or L107F/A316V/K440R variant viruses were all
lower than in mice infected with NY99ic (Table 2), although
these differences were not statistically significant (Student's t
test, P > 0.05). At day 5 post-infection, all mice had signs ofTable 2
Replication and virulence characteristics of NY99ic virus and neuroinvasion
attenuated variants following intracranial inoculation of 3- to 4-week-old NIH
Swiss mice with 1000 pfu of virus
Virus Average titer ± SD a (pfu/brain) AST ±
SDb
(days)
Day 2 Day 5
NY99ic 2.8 ± 2.0 × 106 3.3 ± 0.7 × 109 6.3 ± 0.5
L107F 3.8 ± 2.4 × 105 1.1 ± 0.2 × 108 7.0 ± 0.0
L107F/A316V/K440R 8.6 ± 5.9 × 104 1.9 ± 0.2 × 108 6.8 ± 0.5
a Average virus titer ± standard deviation, determined by plaque assay of brain
homogenates from three animals per virus at each time point post-infection.
b Average survival time ± standard deviation for four animals.illness (ruffled fur, lethargy, some hind limb paralysis), although
average brain titers for the variant viruses were >1 log10 lower
than for NY99ic (P < 0.05). All remaining mice succumbed to
infection, although survival times for mice inoculated with the
variant viruses were slightly prolonged compared to NY99ic
(Table 2). Nucleotide sequencing of the prM and E genes of
virus in the brains of dead mice identified no reversions or
additional mutations for the L107F or L107F/A316V/K440R
variants.
These results suggested that the attenuating L107F mutation
had some impact on the replication of WNV following i.c.
inoculation but that this was insufficient to prevent a lethal
outcome.
Additional L107 mutants
Two non-conservative fusion loop mutants, L107T and
L107D, were also constructed to see if greater attenuation of
NY99 was possible. Both of these substitutions had pre-
viously been shown to more strongly inhibit the activity of
tick-borne encephalitis virus (TBEV) recombinant subviral
particles in in vivo fusion assays compared to an L107F
substitution (Allison et al., 2001). WNV NY99ic mutants
encoding these substitutions were recovered from transfection
cultures at low titer only (<102 pfu/mL), and both reverted to
wild-type sequence after only one or two additional passages
in Vero cells, suggesting that these two substitutions were
not well tolerated and would be of little utility for vaccine
development.Fig. 2. Binding of anti-West Nile virus monoclonal antibodies 5H10, 3A3, 5C5,
7H2 and 3D9 in Western blots against infected Vero cell lysate antigens for
NY99ic mutants encoding amino acid substitutions at L107F, A316V, K440R or
all three residues. Lanes were loaded with approximately equal quantities of
viral E protein antigens, as determined by Coomassie staining.
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protein epitopes
Plaque reduction neutralization and Western blot assays
were used to assess the effects of the three E protein subs-
titutions on binding of five commercially available anti-WNV
NY99 MAbs (Bioreliance Corp., Rockville, MD), as described
elsewhere (Beasley and Barrett, 2002). Four neutralizing MAbs
that recognize epitopes in domain III of E (5H10, 3A3, 5C5
and 7H2) all neutralized the mutant viruses (data not shown)
and recognized mutated E proteins encoding L107F, A316Vor
K440R substitutions in Western blots (Fig. 2). However, a non-
neutralizing MAb, 3D9, whose epitope had not yet been
identified, failed to bind to mutants encoding the L107F subs-
titution, suggesting that 3D9 probably interacts at or near the
fusion loop (Fig. 2).
MAb 3D9 has similar cross-reactivity to other anti-fusion loop
MAbs
As many MAbs with binding sites at or near the fusion loop
have broad cross-reactivity with flaviviruses, the specificity of
anti-WNV MAb 3D9 was tested by hemagglutination in-
hibition (HI) against a panel of inactivated mosquito-borne
flavivirus antigens (Table 3). HI titers against these viruses
were all within two-fold, with the exception of Saint Louis
encephalitis virus.
An attenuated vaccine variant of JEV strain SA14,
designated SA14-14-2, also encodes an L107F E protein
substitution compared to the parental strain (Ni et al., 1995).
As expected, MAb 3D9 recognized E protein of strain SA14 in
Western blot but not the SA14-14-2 variant (data not shown).
Discussion
Residue L107 is located within the highly conserved
flavivirus fusion peptide and therefore has been proposed as a
useful target for introducing attenuating substitutions in any
flavivirus vaccine candidate, and substitutions at or near this
residue have previously been associated with attenuation of
flaviviruses (e.g. Goncalvez et al., 2004; Ni et al., 1995).
Compared with YFV 17D that forms the backbone for the
Chimerivax®-WN vaccine candidate, WNV NY99 has much
greater virulence in a mouse model, being both neuroinvasiveTable 3
Hemagglutination inhibition activity of anti-NY99 West Nile virus monoclonal
antibody 3D9 against a panel of flavivirus antigens
Antigen HI titer
West Nile virus 3200
Japanese encephalitis virus 3200
Saint Louis encephalitis virus 800
Dengue virus type 1 1600
Dengue virus type 2 3200
Dengue virus type 3 1600
Dengue virus type 4 1600
Yellow fever virus 3200and neurovirulent with very low LD50. Combinations of amino
acid substitutions in three structurally distinct regions of the
WNV E protein that attenuated mouse neurovirulence of
Chimerivax®-WN compared to YFV 17D also had some atte-
nuating affect on the neuroinvasiveness of WNV NY99, with
the major determinant of attenuation being the L107F
substitution in the fusion loop. Although viruses possessing
the L107F substitution were greatly attenuated for neuroinva-
siveness, these variants retained highly neurovirulent pheno-
types that were essentially equivalent to the neurovirulent
phenotype of the parental NY99ic virus. Comparisons of virus
titers in the brains of mice inoculated i.c. with NY99ic virus or
either variant encoding L107F suggested that some reduction in
virus replication did occur, but this was not associated with a
reduction in overall lethality. It is important to note that, as we
have observed, the relative effects of any single substitution, or
combination of substitutions, may vary depending upon the
context of the entire genome into which they are introduced
(e.g. WNV NY99 vs. Chimerivax®-WN) and the relative
sensitivity of the model(s) used to measure changes in virus
phenotype.
The L107F substitution appeared to be stable during
passaging in cell culture, although evidence of reversion to
the wild-type sequence at this site was identified in viral
genome products amplified from the brains of two mice that
succumbed to infection following i.p. inoculation with the triple
mutant virus. However, the presence of easily detectable mutant
sequence encoding L107F in each of the brain homogenates
with evidence of reversion suggests that neuroinvasion was
probably effected by the mutant variant encoding L107F prior
to the emergence of significant quantities of revertant virus. No
reversions or additional mutations were identified in prM-E
gene sequences obtained from the brains of mice that died
following i.c. inoculation with either the L107F or L107F/
A316V/K440R variants.
The ability of anti-WNV MAb 3D9 to distinguish between
mutant and wild-type fusion loop sequences could make it a
useful tool for monitoring the stability of substitutions
introduced at residue 107 in WNVand JEV vaccine candidates.
Furthermore, the failure of MAb 3D9 to bind WNV E protein
encoding a L107F substitution was similar to two non-
neutralizing MAbs raised against tick-borne encephalitis virus
(TBEV), 6E2 and 2B6 (TBEV E epitopes A1 and A2, res-
pectively), whose binding was abolished or strongly reduced by
an L107F substitution in that virus (Allison et al., 2001). Both
MAbs had strong hemagglutination inhibition (HI) activity, and
both were broadly cross-reactive with other flaviviruses
(Guirakhoo et al., 1989). An L107K substitution in dengue
virus type 2 E protein abolished binding of a neutralizing,
flavivirus cross-reactive MAb, 4G2, to that virus (Crill and
Chang, 2004), and 4G2 also failed to bind to E proteins of WNV
variants encoding the L107F substitution in Western blots (data
not shown). Clearly, the region around the conserved fusion
loop is a target for antibodies with broad flavivirus cross-
reactivity, although there seem to be significant variations in the
reported ability of these antibodies to neutralize virus infection.
Further studies are needed to elucidate the reasons for these
39S. Zhang et al. / Virology 353 (2006) 35–40differences in the functional activity of antibodies binding at or
near the fusion loop.
These results confirmed that structurally and functionally
conserved regions of the E protein, such as the fusion loop, offer
attractive targets for substitutions that may attenuate many or all
flaviviruses. As our understanding of the mechanisms and
determinants of flavivirus attenuation continue to improve, the
successful development, testing and application of rationally




The WNV NY99 infectious clone used here was a two-
plasmid system from which full-length genome template was
derived by restriction digestion and in vitro ligation as described
elsewhere (Beasley et al., 2005). Viral genomic RNA was
transcribed using the Ampliscribe T7 kit (Epicenter Technol-
ogies, Madison, WI) with m7-GpppA cap analog (New England
Biolabs, Beverly, MA) and electroporated into Vero cells for
recovery of infectious virus. Mutations were introduced into the
plasmid containing the E protein coding region using the
QuikChange II site directed mutagenesis kit (Stratagene, La
Jolla, CA) with primers designed according to the manufac-
turer's recommendations (sequences available on request).
Titers of recovered virus stocks were determined by plaque
assay in Vero cells, and prM and E protein coding regions and/
or complete genomes were sequenced as described previously
(Beasley et al., 2003, 2005) to confirm integrity of the
introduced substitutions.
Mouse virulence testing of WNV variants
Groups of 3- to 4-week-old female NIH Swiss mice (Harlan,
Indianapolis, IN), which are highly susceptible to infection with
NY99 WNV (Beasley et al., 2002), were inoculated intraper-
itoneally (i.p.) or intracranially (i.c.) with serial 10-fold
dilutions (1000–0.1 pfu; 5 mice/dose) of wild-type NY99ic or
mutant viruses for determination of LD50 values.
For more detailed comparison of neurovirulence character-
istics, groups of ten mice were inoculated i.c. with 1000 pfu of
wild-type NY99ic or the L107F or L107F/A316V/K440R va-
riants. Three mice from each group were sacrificed on days 2
and 5 post-infection and their brains homogenized for deter-
mination of viral titers by plaque assay (Beasley et al., 2005).
The remaining four mice in each group were used to compare
survival rates and average survival times.
Antibodies and serological comparisons
Stocks of anti-WNV MAbs 7H2, 5H10, 5C5, 3A3 and 3D9
were obtained commercially (Bioreliance, Rockville, MD).
Previous studies had shown that 7H2, 5H10, 5C5 and 3A3
recognized related but distinct epitopes located on the upper
surface of structural domain III of the E protein, while 3D9recognized an unidentified epitope located outside domain III
(Beasley and Barrett, 2002; Li et al., 2005). Ascitic fluid for
flavivirus cross-reactive MAb 4G2 was kindly provided by Dr.
Steve Higgs (UTMB).
Antigens for Western blotting were prepared by infecting
Vero cell monolayers with wild-type and mutant infectious
clone-derived virus stocks. At the onset of cytopathic effect,
infected monolayers were lysed with 10% SDS and the lysates
incubated at 56 °C for 30 min prior to electrophoresis on non-
denaturing 10% SDS-PAGE gels. Separated proteins were
transferred to nitrocellulose membranes and probed using the
MAbs diluted 1:10,000 (7H2) or 1:2500 (others). Antibody
binding was detected using peroxidase-labeled anti-mouse Ig
antiserum (Sigma, St. Louis, MO) and ECL Western blotting
chemiluminescent substrate (Amersham Biosciences, Piscat-
away, NJ).
HI assays using MAb 3D9 were performed using standard
protocols (Beaty et al., 1989) against inactivated, sucrose–
acetone-treated suckling mouse brain flavivirus antigens ob-
tained from the World Reference Center for Emerging Viruses
and Arboviruses. For each assay, 8 HA units of antigen were
used.
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